Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Zurex Pharma
Zurex Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Zuragard
Fenofibrate
2019-04-26
2024-2033
Hypercholesterolemia
,
Coronary artery disease
,
Dyslipidemias
,
Hypertriglyceridemia
,
Hyperlipoproteinemias
,
Periodontal diseases
,
Infectious skin diseases
,
Gram-negative bacterial infections
,
Oral candidiasis
,
Gram-positive bacterial infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fenofibrate
surgical wound infection
Riboprine
aspergillosis
,
invasive pulmonary aspergillosis
,
inflammation
,
pleural effusion
,
immunosuppression therapy
,
ventilator-associated pneumonia
,
pneumonia
,
pulmonary aspergillosis
Zuraprep
surgical wound infection
Chloraprep
preoperative care
,
infections
,
communicable diseases
Corsodyl
healthy volunteers/patients
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use